This clinical trial is focused on studying a type of liver cancer known as hepatocellular carcinoma. The study is exploring the effects of adding a medication called Ipilimumab to a combination of two other medications, Atezolizumab and Bevacizumab. These medications are given as solutions through a vein, a method known as intravenous infusion. The purpose of the study is to evaluate whether this combination of treatments can improve outcomes for patients receiving their first systemic therapy for this type of cancer.
Participants in the study will be divided into two groups. One group will receive the combination of Atezolizumab and Bevacizumab, while the other group will receive all three medications, including Ipilimumab. The study will last for a period of up to 24 months, during which the effects of the treatments will be monitored. The main goal is to see if the addition of Ipilimumab can help improve the overall survival of patients compared to the two-drug combination. The study will also look at how well the cancer responds to the treatments and how long patients can live without the disease getting worse.
Throughout the study, participants will receive regular check-ups to monitor their health and the progress of their cancer. The study aims to provide valuable information on whether the addition of Ipilimumab offers a significant benefit in treating hepatocellular carcinoma. Participants will be closely observed for any side effects or changes in their quality of life during the treatment period. This research could potentially lead to improved treatment options for patients with this type of liver cancer.
France 
